New hope for recurrent ovarian cancer: Triple-Drug combo trial launches

NCT ID NCT07261683

First seen Jan 05, 2026 · Last updated Jun 13, 2026 · Updated 22 times

Summary

This study tests a combination of three drugs—weekly paclitaxel (or nab-paclitaxel), pembrolizumab, and mirabegron—in adults whose ovarian cancer has returned. The main goal is to see if this treatment shrinks tumors and to check for side effects. About 20 participants will take the drugs and visit the clinic every two months for checkups.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Obstetrics and Gynecology Hospital of Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, 200090, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.